Advantage Sun Pharma As Tel Aviv Court Rules Out Special Tender Offer For Taro Shares
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Sun Pharmaceutical has emerged victorious in the protracted battle with Taro Pharmaceutical in its bid to acquire control of the Israel headquartered company. A Tel Aviv District Court rejected Taro's contention for a special tender offer under Israeli law before Sun Pharma could proceed with its objective to gain control of Taro management
You may also be interested in...
Israeli Supreme Court Directs Sun Pharma To Extend Tender Offer Deadline For Taro
MUMBAI - Sun Pharmaceutical has extended the last date of its tender offer for purchase of outstanding ordinary shares of Taro to Oct. 3, from the previously fixed date of Sept. 3. Sun had to extend the last date to comply with an order by the Supreme Court of Israel temporarily prohibiting the closing of the offer. The tender offer will be valid until the new date unless further extended or earlier terminated
Israeli Supreme Court Directs Sun Pharma To Extend Tender Offer Deadline For Taro
MUMBAI - Sun Pharmaceutical has extended the last date of its tender offer for purchase of outstanding ordinary shares of Taro to Oct. 3, from the previously fixed date of Sept. 3. Sun had to extend the last date to comply with an order by the Supreme Court of Israel temporarily prohibiting the closing of the offer. The tender offer will be valid until the new date unless further extended or earlier terminated
War Of Words Back Between Taro, Sun Pharma; Both Vow to Wrest Taro Control
MUMBAI - The battle for control of Israeli generic drug maker Taro is set to heat up further as Indian drug maker Sun Pharmaceuticals and Taro separately vowed their resolve to retain and acquire control of the beleaguered company